“A Multicenter, Open Label, Phase 1 Study of the Safety, Tolerability, Systemic Exposure, Pharmacodynamics, and Treatment Effect of Calcipotriene Foam, 0.005% in Pediatric Subjects (ages 2 to 11 Years) With Plaque Psoriasis”. SKIN The Journal of Cutaneous Medicine 3 (November 9, 2019): S18. Accessed April 17, 2026. https://skin.dermsquared.com/skin/article/view/745.